About Microviable Therapeutics

Microviable Therapeutics develops microbiota ecosystem products and microbiome therapies, including the orally administered MVT-201 capsule, to treat infectious diseases by utilizing commensal bacteria. Their GutAlive® microbiome collection kit preserves anaerobic bacteria viability for accurate microbiome analysis, addressing the challenge of maintaining sample integrity during transport.

```xml <problem> Current methods for collecting and transporting stool samples often fail to maintain the viability of anaerobic bacteria, leading to inaccurate microbiome analysis and limiting the potential for developing effective microbiota-based therapies. The degradation of samples during transport affects the reliability of downstream applications such as fecal microbiota transplantation (FMT) and bacterial isolation. </problem> <solution> Microviable Therapeutics offers GutAlive®, an anaerobic microbiome collection kit designed to preserve the integrity and diversity of microbiota samples during collection and transport. The kit maintains an anaerobic atmosphere, ensuring the survival of oxygen-sensitive bacteria and the stability of DNA. GutAlive® enables the isolation of a wide range of bacterial genera and supports various downstream applications, including microbiome analysis, bacterial isolation, and the development of microbiota-based therapeutics. The kit's design standardizes sample collection, minimizing variations and maintaining the original composition of the microbiome. </solution> <features> - Anaerobic atmosphere to maintain the viability of oxygen-sensitive bacteria - Maintains bacterial viability and DNA stability during transport - Suitable for both anaerobic bacteria isolation and microbiome analyses - High-capacity container that can fit up to 120 grams of stool sample - Sample stability for over 72 hours without refrigeration - Standardizes sample collection and transport </features> <target_audience> The primary customers are pharmaceutical, biotech, and food industry companies, as well as researchers and clinicians involved in microbiome analysis, biotherapeutic development, and personalized medicine. </target_audience> ```

What does Microviable Therapeutics do?

Where is Microviable Therapeutics located?

Microviable Therapeutics is based in Gijón, Spain.

When was Microviable Therapeutics founded?

Microviable Therapeutics was founded in 2016.

How much funding has Microviable Therapeutics raised?

Microviable Therapeutics has raised 1600000.

Location

Gijón, Spain

Founded

2016

Funding

1600000

Employees

12 employees

Major Investors

Immunomet Intolerance and Dysbiosis

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Microviable Therapeutics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

microviable.com 10K+

Crunchbase

Founded 2016 – Gijón, Spain

Funding

Estimated Funding

$1M+

Major Investors

Immunomet Intolerance and Dysbiosis

Team (10+)

No team information available.

Company Description

Problem

Current methods for collecting and transporting stool samples often fail to maintain the viability of anaerobic bacteria, leading to inaccurate microbiome analysis and limiting the potential for developing effective microbiota-based therapies. The degradation of samples during transport affects the reliability of downstream applications such as fecal microbiota transplantation (FMT) and bacterial isolation.

Solution

Microviable Therapeutics offers GutAlive®, an anaerobic microbiome collection kit designed to preserve the integrity and diversity of microbiota samples during collection and transport. The kit maintains an anaerobic atmosphere, ensuring the survival of oxygen-sensitive bacteria and the stability of DNA. GutAlive® enables the isolation of a wide range of bacterial genera and supports various downstream applications, including microbiome analysis, bacterial isolation, and the development of microbiota-based therapeutics. The kit's design standardizes sample collection, minimizing variations and maintaining the original composition of the microbiome.

Features

Anaerobic atmosphere to maintain the viability of oxygen-sensitive bacteria

Maintains bacterial viability and DNA stability during transport

Suitable for both anaerobic bacteria isolation and microbiome analyses

High-capacity container that can fit up to 120 grams of stool sample

Sample stability for over 72 hours without refrigeration

Standardizes sample collection and transport

Target Audience

The primary customers are pharmaceutical, biotech, and food industry companies, as well as researchers and clinicians involved in microbiome analysis, biotherapeutic development, and personalized medicine.